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Francesco Maisano 1
1University Heart Center, University Hospital Zurich, Zurich, Switzerland, 2Division of Cardiology and Structural Heart
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Mitral regurgitation (MR) is a frequent valvular disease among patients deemed too high
risk for surgery. Echocardiography along with CT is the primary diagnostic tool for MR
and offers a comprehensive 3D assessment in patient selection and screening for the
optimal treatment method. The direct percutaneous mitral annuloplasty addresses the
underlying mechanisms of functional MR with a less invasive, catheter-based approach.
The here-described techniques proved a sufficient safety profile, delivered significant MR
reduction in most of the cases, and were associated with a notable improvement of
symptoms. Although long-term outcome assessment is needed to support these early
reports, the percutaneous mitral annuloplasty is likely to set a new standard of treatment
in the forthcoming future.
Keywords: direct percutaneous annuloplasty, mitral annuloplasty, mitral regurgitation, transcatheter valve repair,
mitral valve interventions, mitral valve imaging, patient selection, mitral annulus
INTRODUCTION
Mitral regurgitation (MR) is the most frequent valve disease in developed countries (1). Referred
to as secondary or as functional mitral regurgitation (FMR), it is caused by sustained left ventricle
injury in the course of myocardial infarction or certain forms of cardiomyopathy, leading to left
ventricle remodeling. That may result in the displacement of the papillary muscles and mitral
annulus (MA) dilatation, yet the leaflet structure remains usually intact (2). Patients presenting
FMR procure an unfavorable prognosis, resulting in over two-fold highermortality when compared
to primary MR and extremely high risk of heart failure (HF rate at 5 years, 78%) (3, 4).
Building on the years of experience with mitral valve replacement and repair procedures,
together with a desire for a less invasive approach, multiple percutaneous technologies have
emerged as a feasible and convenient therapeutic option for patients withMR. They can be classified
depending on the anatomical and pathophysiological grounds: the indirect and direct annuloplasty,
left ventricle (LV) remodeling devices, and leaflet and chordal repair procedures. This review
aims to summarize current principles for patient selection and pre-procedural planning for direct
transcatheter annuloplasty followed by the procedural know-how.
MITRAL VALVE ANNULUS STRUCTURE AND FUNCTION
The mitral valve complex consists of valvular (annulus, commissures, leaflets) and tension
(papillary muscles, chordae tendineae) components. MA is the functional component of the valve
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characterized by a non-planar, saddle-shape frame, believed to
be involved in reducing stress on the valve elements during
systole (Figure 1) (4). For interventional purposes, the annulus
is regarded as the area of the attachment of the valve leaflets
to the atrial part of the surrounding heart tissue. The anterior
part consists of 1/3 of the valve circumference and incorporates
a fibrous thick tissue, supported at each side of the base of
the leaflet by the left (anterolateral) and right posteromedial
fibrous trigones (5). Of more importance, the MA’s three-
dimensional geometry varies through the cardiac cycle. The
standard correlation between the septolateral (antero-posterior)
and transverse (inter-commissural) diameters of the MA is
measured during systole and typically comes close to 3:4
(Figure 2). This can differ among patients with chronic MR,
specifically when the leaflet coaptation is lost, even in the non-
prolapsing segments (6).
Comprehensive assessment of MA still pose a challenge since
different methods and settings have been used to establish the
cutoff value. Since the 3D shape of MV annulus is other than
simple, only a thorough examination is believed to be sufficient in
clinical practice. The current cutoff for annular dilatation is based
on transesophageal measurements of the end-diastolic antero-
posterior MA diameter derived from a small group of 49 patients
referred to MV surgery. This value is regarded as 35mm and is
still the most widely used in intraoperative setting (7).
In the non-surgical setting, the largest population-based
echocardiographic dataset available to date is that of Dwivedi
et al. This study was conceived specifically to determine standard
mitral and tricuspid annulus dimensions with the use of 2D TTE.
Gender-specific mean diameters of MA were 3.44 cm in males
and 3.11 cm in females at end-systole and 3.15 cm in males and
2.83 cm in females at end-diastole. Interestingly, MA reduction
in systolic phase was found to be up to 25% (8).
Some pivotal structures are closely located to the MA and
should always be thoughtfully considered during all annuloplasty
procedures: (a) the circumflex artery, which runs parallel to MV
plane; (b) the coronary sinus, which lies roughly around the base
of the posterior leaflet; (c) the bundle of His, situated close to
posteromedial commissure; and (d) the non-coronary and left
coronary aortic cusps, located adjacent to the base of the anterior
leaflet (Figure 3). The aorto-mitral curtain, composed mainly of
muscular fibers, while separating aortic and mitral structures,
serves as inch point during systolic phase for counterbalancing
the mitral tethering forces (9).
ANNULOPLASTY TECHNIQUES
The implementation of annuloplasty technique in the mitral
valve repair has been initially developed in the surgical setting to
restore the normal annular shape and dimensions by correcting
Abbreviations: MR, mitral regurgitation; FMR, functional mitral regurgitation;
HF, heart failure; LV, left ventricle; MAC, mitral annular calcification; CT,
computed tomography; TEE, transesophageal echocardiography; MA, mitral
annulus; LV, left ventricle; LAD, left anterior descending (artery); LA, left atrium;
AF, atrial fibrillation; PL, posterior leaflet; AL, anterior leaflet; CABG, coronary
artery bypass grafting; ICE, intracardiac echocardiography.
posterior annular dilatation in symptomatic FMR patients. A
standard surgical treatment comprises of annular ring reduction,
aiming to improve leaflet apposition, relieve tension on the
leaflets by optimizing the coaptation zone, preserve leaflet
mobility, and prevent further annular dilatation.
There are various surgical annuloplasty devices on the
market, including flexible or semirigid rings. Ring sizing is
performed following Carpentier’s principles, while the intra-
operative measurement involves the intercommissural diameter
and the area of the anterior leaflet.
Transcatheter annuloplasty has been developed in the field
of transcatheter MV repair to fill the therapeutic gap for high-
risk surgery patients with FMR and to prove its position as
a solid percutaneous alternative to the edge-to-edge treatment
or an adjuvant strategy among the FMR patients. In the
recently published study, apart from the improvement of
mitral parameters and symptoms, the investigators demonstrated
that the use of Cardioband (Edwards Lifesciences) might
result in lower rehospitalization and mortality when compared
to MitraClip treatment (Abbott), especially when low-LVEF
patients are concerned (10).
There are currently a number of devices under investigation
for both indirect and direct percutaneous approach. Indirect
techniques depend on the device introduction and placement
within the MA through the parallel coronary sinus, whereas
direct annuloplasty requires retrograde access to the left ventricle
or trans-septal puncture. The latter techniques deliver the device
within the close proximity of the MA (Table 1; Figure 4).
The method of direct transcatheter annuloplasty is a
recognized therapy for inoperable MR patients, which offers a
safer profile when compared to conventional surgery. Although
it represents a technically complex procedural approach, it
eliminates some of the anatomical restrictions of the indirect
technique. These limitations comprise the variable distance
between the coronary sinus and the annular plane, as well as
the frequently close location of the circumflex artery exposed
to iatrogenic injury. To date, there are two CE-approved direct
annuloplasty devices, the Cardioband (Edwards Lifesciences) and
the Mitralign (Mitralign Inc.).
PROCEDURAL PLANNING AND
ECHOCARDIOGRAPHIC EVALUATION FOR
PATIENT SELECTION
Patients referred to transcatheter mitral valve repair are those
whose high surgical risk represents a main contraindication
for open-heart valve treatment. The exception to this standard
may be considered when a concomitant coronary artery disease
requires adjuvant revascularization. When a patient is deemed
inoperable, anatomical factors should carefully be considered for
the selection of the appropriate intervention. Echocardiography,
mostly TEE, is decisive for this aim.
Echocardiographic Evaluation of FMR
The FMR is typically characterized by the unaltered leaflet
structure; however, one should expect other abnormalities
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FIGURE 1 | The saddle-shape configuration of the mitral valve. The nonplanar shape is believed to significantly reduce the mechanical strains on the posterior leaflet
during systole and optimize force distribution among mitral apparatus.
FIGURE 2 | Transesophageal echocardiography (TTE): (A) intercommissural view focused on MV for intercommissural diameter measurement; (B) mid-esophageal
Long-axis view (ME LAX View) for septo-lateral (antero-posterior) annulus measurement.
(e.g., ruptured chords, flail leaflet) that would imply primary
pathology. In addition, quantitative assessment of some mitral
apparatus structures facilitates the understanding of the valve
disease etiology and may influence future screening and
procedural planning (Figure 5).
The presence of leaflet apical tethering resulting in the apically
displacement of coaptation point is a decisive echocardiographic
feature of FMR. Noteworthy, the leaflet tethering forces cause
impaired leaflet coaptation within the annular plane, resulting in
incomplete closure. Carpentier’s classification of dysfunction is
based on the opening and closing motions of the mitral leaflets in
relation to the annular plane. The FMR can be defined according
to Carpentier mechanisms as type I and type III (11). Type
I FMR is less frequently causing severe MR and it is related
to annular dilatation with normal leaflet motion. Isolated LA
dilation, without LV enlargement or dysfunction, was previously
demonstrated to be not sufficient for determining significant
FMR (12). On the contrary, a recent study revealed that mitral
leaflet area (MLA) adaptation, which occurs as a compensatory
mechanism among patients presented with atrial fibrillation
(AF) and isolated annular dilatation without LV dysfunction,
becomes insufficient with greater annular dilatation (13, 14).
The prevalence of type I FMR is growing due to aging of the
population, increasing prevalence of concomitant long-standing
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FIGURE 3 | Atrial view of mitral valve. Components of mitral valve apparatus and the adjacent structures. The posterior leaflet of the mitral valve composes ∼3/5 of
the annular circumference and comprises three individual scallops identified as P1 (anterior or medial scallop), P2 (middle scallop), and P3 (posterior or lateral scallop).
The three corresponding segments of the anterior leaflet are A1 (anterior segment), A2 (middle segment), and A3 (posterior segment).
TABLE 1 | Currently available transcatheter direct annuloplasty systems
(transapical approach devices have not been listed).
Cardioband
(Edwards
Lifesciences)
Mitralign
(Mitralign Inc.)
Millipede
(Boston Scientific
Corp.)
Access Transseptal Retrograde Transseptal
Position Supra-annular Cross-annular Supra-annular
Repositionable Yes Yes Yes
Clinical status CE Mark CE Mark Investigational use
persistent AF, and impaired LV diastolic function. In non-
ischemic MR, usually the tethering is symmetric and the jet is
central (Figure 5).
In the incidence of ischemic FMR (type IIIb), the displacement
of the papillary muscles and distortion of LV directly alter
the geometry and function of the mitral valve apparatus.
Although both papillary muscles are frequently affected, it is
the dysfunction of posterior papillary muscle that prevails and
results in the tethering of the posteromedial leaflet segment (P3)
(Figure 6). Hence, FMR jet is usually eccentric and directed
posteriorly along the P3 area (Figure 7) (15). However, in the
case of unpopular LAD infarction, the large central MR jets
mark the preceding broad ischemia of the papillary muscles
and other affected LV segments (16). With the increase of
lateral and apical forces, the leaflet tethering predominates over
annulus dilatation. In that case, the annuloplasty as a stand-
alone procedure is typically not a sufficient repair therapy.
Numerous surgical methods have been introduced to address
the left ventricle dilatation (e.g., papillary muscle approximation,
ventricular containment/ventriculoplasty). Nonetheless, having
in mind further LV remodeling in the course of the secondary
MR, the “downsizing” of the mitral annuloplasty (i.e., restrictive
mitral ring implantation) may be recommended (14, 16, 17).
Patient Selection and Success Predictors
of Annuloplasty Techniques
Echocardiographic assessment should consistently clarify if the
mechanism of MR is functional and at the same time evaluate
the LV dimension and function to distinguish type I from
type III FMR. Once the MR mechanism is determined, further
TEE assessment is crucial for selecting the suitable patient
for the right procedure (see section Anatomical Factors: MV
Leaflet Tethering).
Presuming that MR is successfully treated with MitraClip,
given the large amount of evidence, transcatheter edge-to-
edge treatment may be regarded as a first-line procedure.
Nonetheless, in the case of annular dilatation, one should
consider annuloplasty techniques. In fact, this procedure “leaves
the door opened” to other supplementary treatment (18, 19).
Evaluation of remodeling of MV apparatus and LV can
facilitate the prediction of the MR recurrence after annuloplasty.
From an anatomical perspective, the rationale of both surgical
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FIGURE 4 | Currently available transcatheter direct annuloplasty systems: (A) Cardioband (Edwards Lifesciences); (B) Mitralign (Mitralign Inc.); (C) Millipede (Boston
Scientific Corp.). Image Courtesy of Millipede, Inc. www.millipedemedical.com All rights reserved.
FIGURE 5 | Long-axis view of the LV and MV apparatus. Coaptation length, height, and tenting area are among key measurements in the preoperative planning and
screening.
and transcatheter annuloplasty depends on shifting the posterior
annulus anteriorly, reducing the septolateral distance and
increasing the coaptation area. However, this mechanism does
not settle anteriorly the coaptation point, since the posterior
leaflet struggles being tethered posteriorly and its anterior
excursion is noticeably limited. This phenomenon of “freezing
of posterior leaflet” is always present after annuloplasty and does
not affect the anterior leaflet (AL) motion, so that valve closure
becomes essentially a “single-leaflet process” and the frozen
posterior leaflet (PL) serves only as a support for the closure (16).
Anatomical Factors: MV Leaflet Tethering
Some MV geometry parameters have been found to be
independent predictors of the recurrence of MR after MV
ring annuloplasty. Previous studies have demonstrated that
poor outcomes of the surgical annuloplasty may be associated
with greater preoperative leaflet tethering. Calafiore et al. have
determined that a coaptation distance of more than 1.1 cm
might be associated with a high risk of MR recurrence after
surgery (17). Likewise, a similar study of patients who underwent
ring annuloplasty revealed that one should consider a posterior
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FIGURE 6 | Carpentier type I mitral regurgitation (depending from annular dilatation). Normal leaflet motion. Regurgitation jet directed centrally.
FIGURE 7 | Left ventricle and mitral valve—side view (LVOT was not depicted). The restricted leaflet motion and tethering in the course of posterior papillary muscle
ischemia predominantly affects the posteromedial leaflet segment (P3).
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FIGURE 8 | Carpentier type III mitral regurgitation. Restricted leaflet motion. Regurgitation jet directed eccentrically.
leaflet angle of more than 45◦, a tenting area above 2.5 cm2,
and the coaptation distance of more than 1 cm to predict
the persistence of more than moderate MR after surgical
annuloplasty (19). Considering the small amount of data of new-
generation annuloplasty techniques, these parameters might also
serve as a reference for transcatether MV repair (19–21).
A tethering direction has been regarded as a determinant for
the symmetry of the leaflet restriction. The properly functioning
chordae system comprises the marginal part that fixes the free
edges of both mitral leaflets and the stiffened basal part that
constitute the base of the ventricular side of AL. Anterior leaflet
tenting angles can be identified as basal and apical (Figure 8).
Since the insertion points of chordae vary, the direction of
tethering forces creates different geometrical shapes of tenting
area and leaflets. When the posterior tethering predominates,
the tethering of the basal chordae on the medial part of AL is
more pronounced than the tethering of distal-primary chordae
on the anterior leaflet tips. As a result, the AL structure tends
to bend. This effect might be restored by reducing the posterior
dilatation and the tethering on basal chordae. However, in the
incidence of the apical tethering of both leaflets, the motion
of distal AL is usually restricted, creating more challenging
conditions for the successful annuloplasty (22). Hence, jet
eccentricity, direction, and distal anterior leaflet tenting angle
are currently regarded as the determinants for predicting the
success of annuloplasty techniques, more than a basal anterior
leaflet tenting angle and posterior tenting angle (23, 24). Annular
size and calcifications as well as the proximity of the circumflex
artery are also acknowledged factors of the feasible and successful
direct annuloplasty.
Functional Factors: Left Ventricle Remodeling
Many studies, including more than 700 patients treated with MV
annuloplasty, sought to identify the factors that correlate with
mitral annuloplasty outcomes. In one analysis, the investigators
revealed that the recurrence of MR within the first 6 months was
associated with higher grade of preoperative MR, smaller body
size, early date of operation, jet direction other than posterior
(essentially central or complex), and the Peri-Guard annuloplasty
technique (25). Subsequent MR recurrence (>6 months) was
related to severe preoperative left ventricular dysfunction (26).
More recently, a re-analysis of 214 patients with ischemic
FMR by the Cardiothoracic Surgical Trials Network (CTSN)
investigators, has demonstrated that the 1-year recurrence of MR
is linked to LV end-systolic diameter/ring size mismatch, after
adjustment for age, sex, and baseline LVEF. A basal aneurism
or dyskinesis of LV was associated with significant recurrent
MR, rebating the role of higher LV–MV ring mismatch that is
obviously more pronounced in case of basal aneurysms (26, 27).
In a small group of patients undergoing MV ring annuloplasty, it
was demonstrated that the LV sphericity index, calculated at end-
systole as the volume of LV divided by the volume of a sphere
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TABLE 2 | Predictors of failure of annuloplasty evaluated in surgical setting.
Predictors of recurrent MR after surgical annuloplasty
Short-term results
Distal anterior leaflet angle tethering
Leaflet tethering: tenting depth (height) and tenting area
Higher grade of preoperative MR
Smaller body size
Early date of operation
Jet direction other than posterior (essentially central or complex)
Peri-Guard annuloplasty technique
Mid- and long-term results
Severe LV dilatation and dysfunction
LV sphericity
Ratio between LVESD/ring size (mismatch)
Basal aneurysm/dyskinesis
Clinical factors/past history (age, body mass index, sex, race, NYHA, prior
CABG, prior percutaneous coronary intervention, and history of ventricular
arrhythmia)
with a diameter equal to the LV longest axis (measured in apical
view), was the best predictor of long-term recurrent MR. Indeed,
this parameter conveys the degree of tethering, as the more
spherical is the LV, the more the displacement of the papillary
muscle (25). Keeping in mind that advanced LV remodeling is
associated with worse outcomes, in the subgroup of patients
with enlarged ventricle and great tenting height (particularly
>11mm), not only the annuloplasty, but a subvalvular repair
might be necessary (28).
It has to be noted that all these factors (anatomical and
functional) derive from surgical setting and further studies are
necessary to prove them as predictors of the recurrence of MR
after transcatheter annuloplasty. Despite the lack of evidence,
these criteria can be useful in preoperative evaluation of patients
candidate to transcatheter annuloplasty for predicting the risk of
procedural failure. Noteworthy, in the intraprocedural setting of
transcatheter intervention, these factors can be re-evaluated right
after the restrictive annuloplasty in order to plan further staged or
even combined interventions (Table 2) (17, 18).
CORONARY ANGIOGRAPHY AND
COMPUTED TOMOGRAPHY (CT)
The presence and significance of possible coexisting coronary
artery disease need to be documented; therefore, coronary
angiography is routinely performed. Over the years, together
with a rapid development of percutaneous interventions,
computed tomography imaging has become a decisive tool
for the preprocedural planning and implant selection. CT
reconstructions allow a comprehensive assessment of mitral
valve anatomy and can be a valuable tool to predict procedural
challenges such as the proximity of the adjacent structures, in
particular the circumflex artery and the risk of its injury (29, 30).
Along with the MV annular size and aortic and mitral valve
correlations, the optimal transseptal puncture site is selected.
Secondly, the posterior annulus is divided into multiple regions
to identify the right position and indicate the anchor angle.
Finally, optimal fluoroscopic planes for implantation should be
estimated. Keep in mind that mitral annular calcification might
be considered as a contraindication for mitral annuloplasty,
as severe MAC hinders optimal anchoring and contracting of
the implant and may also deteriorate echocardiographic image
quality (Figure 9).
CARDIOBAND MITRAL SYSTEM
(EDWARDS LIFESCIENCES)
The early experience with the Cardioband proved that this
direct annuloplasty device is feasible, safe, and effective.
The implantation is performed under general anesthesia with
fluoroscopy and 3D-echo guidance in a stepwise fashion. While
proceeding with the procedure, everymove is reversible, resulting
in a legitimate safety level and control.
The Cardioband system uses a transseptal steerable sheath
(TSS) that is delivered over a super-stiff guide wire via the femoral
vein into the left atrium by a standard transseptal puncture.
By that time, make sure to obtain an activated clotting time
between 250 and 300 s. The steerable sheath facilitates the optimal
positioning of the implant catheter possibly close to the leaflet
hinge, near the anterior commissure. Verification of the first
anchoring location is crucial and requires echo supervision to
prevent the damage of surrounding structures. To rule out
the risk of circumflex artery injury, coronary angiography is
performed. The use of a standard 0.014′′ coronary wire may
serve as a radiographic marker and a potential railway for bailout
PCI-LCx. Regardless of the assessment, the operator needs to
be prepared for a possible bail-out scenario (Figure 10) (31).
The depicted vessel might also serve as a useful reference to
guide the procedure. After the first implant is delivered at
the anterolateral trigone and its position is verified, a set of
anchors is advanced through the polyester sleeve into the annular
part in the posterior and medial correspondence to the first
implant. Every anchor is deployed until the radiopaque marker
on the Implant Catheter Channel reaches the next marker on the
implant. Before every release, the operator needs to verify proper
anchoring of the implant with “push-and-pull test” under echo
and fluoroscopic guidance. Please note that the implantation
of the anchors with an angle of 45◦ can improve the fixation
permanence. The number of anchors depends on the size of the
device implanted and are usually delivered every 8mm until the
Implant Catheter tip reaches the final anchoring position on the
posterior commissure. Usually, during the anchor implantation
into the myocardial tissue, extra-systolic beats on the ECG can
be observed. When the final anchor is deployed, the implant is
detached from the delivery system and removed. Once the entire
device is implanted, the contraction wire with “size adjustment
tool” is advanced over the implant guide wire, until the distal
tip reaches the “adjustment spool” of the implant. The implant is
then contracted by clockwise turn of the “adjustment roller” until
the appropriate size is reached. Typically, a left anterior oblique
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FIGURE 9 | Phenotypes of tethering. (A) Transthoracic echocardiography (TTE), parasternal LAX view: anterior leaflet (AL) tethering with AL bend;
(B) transesophageal echocardiography (TTE), midesophageal 4-CH view focused on MV: less pronounced bend and tip angle of the AL.
FIGURE 10 | Transthoracic echocardiography (TTE); apical 4-CH view. Mitral annular calcification (MAC).
(LAO) projection is used to guide this step. Finally, the obtained
reduction of MR is evaluated by TEE under beating-heart setting
(Figures 11, 12).
The key advantages of the system are adjustable implantation
with the real-time confirmation of the result due to echo-
driven live imaging and the instantaneous improvement of the
patient’s hemodynamics. The device preserves the patient’s native
anatomy, keeping future treatment options open in case of
recurrent MR. The recent studies proved the efficacy and safety
of the Cardioband implantation, which resulted in a significant
MR reduction in majority of patients and was associated with
significant improvement in functional status and quality of life
(32). The ongoing ACTIVE randomized trial is expected to
support these early promising results (NCT03016975).
THE MITRALIGN (MITRALIGN INC.)
The Mitralign uses a retrograde approach to deliver a 14-Fr
guiding catheter through the aortic valve, onto the posterior side
of the left ventricle, beneath the mitral leaflet. Two pairs of wires
are advanced through the MA tissue and deliver the pledges on
both sides of the commissure. The first pledged catheter extrudes
half the pledget on the atrial side and the other on the ventricular
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FIGURE 11 | Integrated intra-procedural guidance for Cardioband: (A,C) real-time 3D transesophageal echocardiography facilitates the navigation and delivery of the
first anchor; (B) fluoroscopy: the use of coronary wire may serve as a radiographic marker and a potential railway for bailout strategies. Fusion imaging allows to
display an overlap image of the “echo-structures” in the fluoro-images. This could be a valuable tool in the presence of difficult anatomies and in the first phase of the
operator’s learning curve.
side. The delivery of the second pledged catheter follows the
same steps. Both anchors are connected by a drawstring, and by
tightening up the sutures, the reduction ofMA is achieved.When
the same steps are followed on the opposite side of the valve, the
procedure is complete. With the Mitralign System, the perimeter
of the annulus can be reduced by as high as 20%. The device
is assigned to FMR patients, addressing MV annular dilatation.
The key advantage of this technique is that the transseptal
puncture is not needed during the procedure. However, in
patients with depressed LV function, the retrograde access may
be less tolerated. In the “Mitralign Percutaneous Annuloplasty
First-in-Man Study,” the device proved the favorable safety profile
while reducing the MR grade and symptoms in 50% of patients
during 6-month observation (33).
MILLIPEDE TRANSCATHETER
ANNULOPLASTY RING (BOSTON
SCIENTIFIC CORP.)
The direct transcatheter-based annuloplasty approach from
Millipede features a complete semi-rigid ring designed to
reproduce the surgical MV repair. The delivery system includes
the guide catheter, the delivery catheter, and the ICE catheter.
Introduced by transfemoral, the venous approach is delivered
through the transeptal puncture above the mitral valve annulus.
The delivery catheter settles the device supra-annularly just
before the anchoring. Finally, the ring is clinched, resulting
in the annular size reduction (anterior–posterior diameter).
The mechanism is designed to provide reposition and retrieve
options during the procedure, while preserving the possibility for
further sub-valvular treatment after complete implantation. The
procedure is guided by the compound, but standard imaging:
fluoroscopy to assess the atrium, TEE to land the device, and
ICE to locate the anchors. The introduced steering method
facilitated by the ICE imaging might be particularly convenient
for experienced MitraClip implanters. To date, the device proved
encouraging safety profile and efficacy in reducing MR. The
technology is still under development and not available for
commercial use (34).
CONCLUSIONS
Patients with severe MR regarded too high risk for surgery can
benefit from novel percutaneous approaches. Current imaging
modalities have contributed to understanding the etiology and
anatomy of MR, and are an integral part of preprocedural
planning. Considering that TEE and CT offer a comprehensive
3D assessment, they are regarded as the gold standard for MR
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FIGURE 12 | Pre- and post-implantation echo and fluoroscopy images. TEE 2-CH and LAX projections demonstrating visibly reduced regurgitation jet. Fluoro images
showing the process of deployment and clinching of the annuloplasty ring concluded with a successful implantation.
evaluation and the optimal patient selection. The enhanced live
visualization of the mitral apparatus due to the fusion of 3D-echo
and fluoroscopy can providemore intuitive imaging and facilitate
the intraprocedural guidance at any stages of the annuloplasty
procedure (33).
The direct percutaneous mitral annuloplasty addresses the
underlying mechanisms of FMR with a less invasive, catheter-
delivered approach. In previously conducted studies, based on
surgical experience, the investigators demonstrated that the
combination of leaflet repair with surgical annuloplasty has a
potential for a lower rate of MR recurrence (35). Although the
percutaneous annuloplasty devices are primarily intended for the
stand-alone treatment of FMR, the simultaneous usage of two
therapies may become an alternative strategy for some subgroups
(36). Therefore, Latib et al. proved the feasibility of percutaneous
direct annuloplasty as a treatment option for patients with FMR
previously subjected to MitraClip and presented with persistent
annular dilation and recurrent MR. As in surgical setting, the
direct transcatheter annuloplasty may serve as a part of the
combination strategy with a percutaneous edge-to-edge repair
for individuals with a functional impairment of mitral valve and
asymmetric tethering to obtain lower rates of MR recurrence.
Yet, this has to be proven in further clinical trials. Moreover,
some patients screened for MitraClip are considered unsuitable,
indicating that there is a clinical need for an adjunctive
transcatheter mitral repair strategy (37–39). This group primarily
includes individuals with calcified or rheumatic deformed leaflets
and substantial annular dilatation. Although there has not been
any cutoff for the annular dimension established, one may
consider a range between 40 and 45mm too much for the edge-
to-edge therapy as a first-line procedure. However, in some cases,
despite the extensively dilated annulus, the length of the leaflets
may still allow sufficient coaptation. One should consider isolated
annuloplasty procedure for an early treatment of the FMR, while
the ideal patient for that indication might be regarded as the one
with limited tethering of the posterior leaflet or with the isolated
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atrial enlargement with a concomitant annular dilatation (in the
absence with LV remodeling).
The recently published propensity matched analysis of
registry data demonstrated that both edge-to-edge treatment
and direct annuloplasty effectively reduce MR and heart failure
symptoms. However, FMR patients treated with Cardioband
proclaimed more notable improvement regarding NYHA scale,
rehospitalization, and mortality, with predominant benefit in the
EF < 30% subgroup (40).
The here-described devices proved to be safe and effective,
providing significant MR reduction in the study group and
significant improvement of symptoms (30, 31). Finally,
the simultaneous training of interventional cardiologists,
cardiosurgeons, and echocardiographers, and reproducibility of
the procedure are the key points to achieve more optimal results
with less procedural times. Having in mind all mitral therapeutic
options, current cardiovascular medicine offers a therapy based
on the mechanism of MR with new approaches likely to set a
new standard of treatment in the forthcoming future.
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